BioMendics Brings New Hope for Epidermolysis Bullosa Simplex Patients as TAMES‑02 Trial Advances and JPM Week Approaches

Core Insights - BioMendics is advancing its TAMES-02 trial for TolaSure™, a potential disease-modifying topical therapy aimed at treating Epidermolysis Bullosa Simplex [1] Company Summary - BioMendics is focused on developing innovative therapies for rare skin conditions, specifically targeting Epidermolysis Bullosa Simplex with its TolaSure™ product [1]